The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee — Sep 26th, 2024

Pacira BioSciences -- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentati...

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders — Sep 25th, 2024

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee — Sep 26th, 2024

Pacira BioSciences -- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentati...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders — Sep 25th, 2024

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee — Sep 26th, 2024

Pacira BioSciences -- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentati...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...